Desotop Gel

Desonide Topical
0.05%
ACI Limited
Pack size 15gm tube
Dispensing mode
Source
Agent
Retail Price 50.34 AED

Indications

Desotop Gel is used for: Psoriasis, Eczema, Contact dermatitis, Corticosteroid-responsive dermatoses, Seborrheic dermatitis

Adult Dose

Topical/Cutaneous Corticosteroid-responsive dermatoses Adult: Apply sparingly onto the affected areas 2 times/day. Discontinue therapy when control is achieved. If no improvement seen within 4 weeks, reassessment of diagnosis may be necessary; treatment beyond 4 consecutive weeks not recommended.

Child Dose

Dermatoses <3 years: Safety and efficacy not established >3 years: Apply gel sparingly to affected area(s) q8-12hr; discontinue therapy if control achieved

Renal Dose

Administration

For topical use only. Not for oral, ophthalmic, or intravaginal use.

Contra Indications

Hypersensitivity to any of the components. Primary infective skin conditions.

Precautions

Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can result from systemic absorption of topical corticosteroids Use medium-to-very high potency topical corticosteroids for <2 wk to reduce local and systemic adverse effects; avoid use on face, folds, groin owing to increased absorption Use low-potency topical corticosteroids for chronic therapy May cause local skin adverse reactions; if irritation develops, discontinue treatment and institute appropriate therapy; allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noticing a clinical exacerbation; corroborate with appropriate diagnostic patch testing If concomitant skin infections are present or develop, initiate appropriate antifungal, antibacterial, or antiviral agent; if favorable response does not occur promptly, discontinue desonide until infection controlled Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma Avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation Because of potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression; factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression; if HPA axis suppression documented, an attempt should be made to gradually withdraw drug, to reduce frequency of application, or to substitute a less potent steroid; manifestations of adrenal insufficiency may require supplemental systemic corticosteroids; recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids

Pregnancy-Lactation

Pregnancy There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes Lactation There are no data on presence in human or animal milk, effects on breastfed infant, or on milk production; unknown whether topical administration could result in sufficient systemic absorption to produce detectable quantities in human milk; developmental and health benefits should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition To minimize potential exposure to breastfed infant via breast milk, use on smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women to wash off any amount that may have been applied to nipple and areola prior to breastfeeding to avoid direct infant exposure

Interactions

Adverse Effects

Side effects of Desonide Topical : Frequency Not Defined Skin atrophy Striae Hypertension Headache Irritability Hyperglycemia Itching Scaly skin Acneform lesions Pigmentation changes HPA suppression (with higher potency used >2 wk)

Mechanism of Action

Desonide is a corticosteroid used mainly for its glucocorticoid activity in the treatment of various skin disorders.

Note

Desotop 0.05% Gel manufactured by ACI Limited. Its generic name is Desonide Topical. Desotop is availble in Bangladesh. Farmaco BD drug index information on Desotop Gel is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Desonide Topical :